BNOX

Bionomics
BNOX

$0.7
6.2%
 

About: Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.

Employees: 8

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

11% more funds holding

Funds holding: 9 [Q4 2023] → 10 (+1) [Q1 2024]

0.01% less ownership

Funds ownership: 0.07% [Q4 2023] → 0.06% (-0.01%) [Q1 2024]

36% less capital invested

Capital invested by funds: $1.92M [Q4 2023] → $1.22M (-$699K) [Q1 2024]

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
1,045%
upside
Avg. target
$8
1,045%
upside
High target
$8
1,045%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
1,045%upside
$8
Buy
Reiterated
12 Jun 2024
HC Wainwright & Co.
Joseph Pantginis
1,045%upside
$8
Buy
Reiterated
21 Mar 2024

Financial journalist opinion